Biocompatible fiducial marker using multi-block copolymers
The present invention relates to a fiducial marker comprising barium sulfate (BaSO 4 ), a solvent, and a polyethylene glycol-poly(aminourethaneurea) multi-block copolymer, as active ingredients. The fiducial marker of the present invention has an effect of significantly remedying disadvantages of image distortion and dose distortion, which are involved in the gold inner marker used in the conventional art. The fiducial marker of the present invention has very limited in vivo mobility, and thus the fiducial marker is maintained at the position at which it has been initially injected. Since the fiducial marker of the present invention is maintained in a sol or liquid state before in vivo injection, and transited into a gel or solid phase after in vivo injection, the injectability of the fiducial marker by an injector syringe is favorable, and the state of the fiducial marker can be controlled into a phase suitable to each site of the therapeutic target.
1. A fiducial marker, comprising: (i) barium sulfate (BaSO 4 ); (ii) a solvent; and (iii) a polyethyleneglycol-poly(aminoureaurethane) multi-block copolymer, as active ingredients,
wherein the content of the barium sulfate (BaSO 4 ) is 10-20 wt %,
wherein the content of the polyethyleneglycol-poly(aminoureaurethane) multi-block copolymer is 1-20 wt %, and
wherein the polyethylene glycol-poly(aminoureaurethane) multi-block copolymer has a repeat unit represented by chemical formula 1 below:
wherein
n1 is an integer of 7 to 50;
n2 is an integer of 2 to 8;
n3 is an integer of 1 to 10; and
m is an integer of 2 to 6.
2. The fiducial marker of claim 1 , wherein the polyethylene glycol-poly(aminoureaurethane) multi-block copolymer has a molecular weight of 15,000 g/mol to 25,000 g/mol.
3. The fiducial marker of claim 1 , wherein in chemical formula 1, n2 is 6.
4. The fiducial marker of claim 1 , wherein in chemical formula 1, n3 is 2.
5. The fiducial marker of claim 1 , wherein the solvent is a buffer.
6. The fiducial marker of claim 5 , wherein the buffer is buffered saline.
7. The fiducial marker of claim 1 , wherein the fiducial marker is used to display the position of a diseased part in the body at the time of radiotherapy.
8. The fiducial marker of claim 1 , wherein the polyethylene glycol-poly(aminoureaurethane) multi-block copolymer is degraded in vivo.
9. The fiducial marker of claim 1 , wherein the fiducial marker is in an injection type in which the fiducial marker is injected into the body in a sol phase.
10. The fiducial marker of claim 1 , wherein the fiducial marker is hardened in a gel phase in the body after in vivo injection.
11. The fiducial marker of claim 1 , wherein the fiducial marker shows a 90% or more reduction in the degree of image distortion compared with a metal fiducial marker.
12. The fiducial marker of claim 1 , wherein the fiducial marker shows a 11.26% or more reduction in the degree of dose distortion compared with a metal fiducial marker.